Oncology,
Health,
Infectious diseases,
General Health,
Clinical trials,
Pharmaceutical,
Biotechnology,
Branches of biology,
Cytokines,
Cell biology,
EMR1,
Granulocyte-macrophage colony-stimulating factor,
Macrophage colony-stimulating factor Management will also participate in a Fireside Chat with Cantor Fitzgerald Analyst Louise Chen on February 26, 2021.
Key Points:
- Management will also participate in a Fireside Chat with Cantor Fitzgerald Analyst Louise Chen on February 26, 2021.
- Humanigen believes that its GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection.
- Humanigen is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity.
- In addition, Humanigen is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders.
Biotechnology,
Pharmaceutical,
Other Manufacturing,
Health,
Infectious diseases,
Genetics,
Manufacturing,
Clinical trials,
Life sciences,
Pharmaceutical industry,
Biotechnology,
Health sciences,
Contract manufacturing organization,
Biopharmaceutical,
Biologics license application Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (Avid) and Humanigen, Inc. (NASDAQ:HGEN) (Humanigen) today announced that they have entered into a manufacturing services agreement to expand production capacity for lenzilumab, Humanigens therapeutic candidate in development for COVID-19.
Key Points:
- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (Avid) and Humanigen, Inc. (NASDAQ:HGEN) (Humanigen) today announced that they have entered into a manufacturing services agreement to expand production capacity for lenzilumab, Humanigens therapeutic candidate in development for COVID-19.
- This collaboration enhances commercial production efforts for lenzilumab in advance of potential filings for emergency use authorization (EUA) and subsequent Biologics License Application (BLA) later this year.
- Lenzilumab is an exciting COVID-19 therapeutic candidate and the type of complex biologic for which Avid possesses decades of manufacturing success.
- Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and cGMP manufacturing of biopharmaceutical drug substances derived from mammalian cell culture.
Health,
Infectious diseases,
Hospitals,
Genetics,
Clinical trials,
Pharmaceutical,
Biotechnology,
Medical specialties,
Immunology,
Medicine,
Branches of biology,
Cytokine storm,
Cytokine,
Lenzilumab,
Coronavirus disease,
Immunoglobulin E Humanigen, Inc. (NASDAQ:HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab, today announced it has completed enrollment for its pivotal phase 3 study of lenzilumab for COVID-19.
Key Points:
- Humanigen, Inc. (NASDAQ:HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab, today announced it has completed enrollment for its pivotal phase 3 study of lenzilumab for COVID-19.
- Completing enrollment in this Phase 3 study is a significant milestone in the clinical development of lenzilumab, said Cameron Durrant, MD, MBA, chief executive officer of Humanigen.
- We are grateful to the trial participants, their families, investigators and healthcare professionals for their contributions and partnership in continuing to advance the development of lenzilumab.
- Data showed that almost 90 percent of hospitalized patients with COVID-19 are at risk of this immune hyper-response.
Infectious diseases,
Biotechnology,
Pharmaceutical,
Health,
Branches of biology,
Cytokines,
Cell biology,
Granulocyte-macrophage colony-stimulating factor,
Lenzilumab,
Ajinomoto,
Coronavirus disease,
Emergency Use Authorization,
Macrophage colony-stimulating factor,
Ajinomoto Bio-Pharma Services,
Humanigen, Inc. Humanigen is actively enrolling patients in a Phase 3 study in the U.S. and Brazil and preparing for a potential COVID-19 Emergency Use Authorization (EUA) for lenzilumab.
Key Points:
- Humanigen is actively enrolling patients in a Phase 3 study in the U.S. and Brazil and preparing for a potential COVID-19 Emergency Use Authorization (EUA) for lenzilumab.
- We are very pleased to be working with Aji Bio-Pharma for the fill finish production of lenzilumab, said Cameron Durrant, MD, MBA, Chief Executive Officer of Humanigen.
- Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our clients needs.
- Humanigen believes that its GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection.
Infectious diseases,
Biotechnology,
Pharmaceutical,
Health,
Life sciences,
Pharmaceutical industry,
Health sciences,
Emergent BioSolutions,
Biotechnology,
Biologics license application,
Contract manufacturing organization,
Emergent,
Biopharmaceutical,
Emergent BioSolutions,
Humanigen, Inc. The parties intend to negotiate a commercial manufacturing services agreement that could include future fill batches for a biologics license application (BLA).
Key Points:
- The parties intend to negotiate a commercial manufacturing services agreement that could include future fill batches for a biologics license application (BLA).
- Partnering with leading CDMOs like Emergent BioSolutions to help us build out our manufacturing capacity is a cornerstone to that strategy, said Cameron Durrant, MD, MBA, chief executive officer of Humanigen.
- This agreement marks Emergents seventh CDMO collaboration with government and industry partners working to deliver COVID-19 vaccine and therapeutic solutions.
- Through Emergents specialty products and contract development and manufacturing services, Emergent is dedicated to providing solutions that address public health threats.
Science,
Other Science,
Biotechnology,
Research,
Pharmaceutical,
Health,
Infectious diseases,
Clinical trials,
Biomedical Advanced Research and Development Authority,
Emergency Use Authorization,
Barda,
Cooperative research and development agreement,
Coronavirus disease,
Health,
Articles,
Medicine The agreement supports development of lenzilumab in advance of a potential Emergency Use Authorization (EUA) for COVID-19.
Key Points:
- The agreement supports development of lenzilumab in advance of a potential Emergency Use Authorization (EUA) for COVID-19.
- The amended CRADA, now co-signed by BARDA, provides Humanigen with access to manufacturing capacity reserved by BARDA for fill-finish product to accelerate the drug product manufacturing of lenzilumab.
- Lenzilumab is currently in a Phase 3 clinical trial evaluating patients hospitalized with COVID-19.
- It has been an honor to have the integrated expert team at BARDA prioritize lenzilumab research and development during this critical time, said Cameron Durrant, MD, MBA, chief executive officer of Humanigen.
Infectious diseases,
Pharmaceutical,
Health,
Clinical trials,
Articles,
Management education,
Master of Business Administration,
Forward-looking statement,
Eua,
Coronavirus disease,
Human activities,
Academic disciplines,
Humanigen, Inc.,
EVERSANA™ The agreement with EVERSANA builds on the commercial preparation and lenzilumab launch planning Humanigen has been conducting over the last several months.
Key Points:
- The agreement with EVERSANA builds on the commercial preparation and lenzilumab launch planning Humanigen has been conducting over the last several months.
- EVERSANA shares our tireless commitment to patients, said Cameron Durrant, MD, MBA, chief executive officer of Humanigen.
- Weve matched our dedication to research and development in COVID-19 with a proven commercialization partner to ensure lenzilumab will reach patients quickly and efficiently following a potential EUA.
- You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release.
Biotechnology,
General Health,
Health,
Clinical trials,
Medical specialties,
Branches of biology,
Clinical medicine,
Sarbecovirus,
Immunology,
Cytokines,
Growth factors,
Zoonoses,
Granulocyte-macrophage colony-stimulating factor,
Cytokine release syndrome,
Cytokine,
Macrophage colony-stimulating factor We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection.
Key Points:
- We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection.
- The companys immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection.
- The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity.
- You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release.
Science,
Other Science,
Biotechnology,
Research,
Pharmaceutical,
Oncology,
General Health,
Health,
Medical specialties,
Clinical medicine,
Medicine,
Immunology,
Monoclonal antibodies,
Lenzilumab,
Immune system,
Cytokine release syndrome,
Coronavirus disease,
Immunotherapy,
Chimeric antigen receptor T cell,
Cytokine (NASDAQ: HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab, today announced the United States Patent and Trademark Office has issued a patent to the Company for the use of lenzilumab in prevention or treatment of cytokine storm and neurotoxicity in patients undergoing chimeric antigen receptor T (CAR-T) cell therapy.
Key Points:
- (NASDAQ: HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab, today announced the United States Patent and Trademark Office has issued a patent to the Company for the use of lenzilumab in prevention or treatment of cytokine storm and neurotoxicity in patients undergoing chimeric antigen receptor T (CAR-T) cell therapy.
- The patent covers the use of lenzilumab to prevent or treat cytokine release syndrome (CRS), neurotoxicity and otherwise inhibit or reduce incidence or severity of CAR-T-related toxicities in patients undergoing CAR-T cell therapy.
- This patent underscores Humanigens pioneering approach to neutralizing GM-CSF with lenzilumab and the value of our robust pipeline across the many disease areas where cytokine storm plays a critical role, including COVID-19 and acute graft-versus-host disease.
- The patent, titled Methods of Treating Immunotherapy-Related Toxicity Using a GM-CSF Antagonist, was issued on December 22, 2020 as U.S. Patent No.
Oncology,
Health,
FDA,
Infectious diseases,
Clinical trials,
Pharmaceutical,
Biotechnology,
Medical specialties,
Branches of biology,
Immunology,
Cytokines,
Clinical medicine,
Monoclonal antibodies,
Granulocyte-macrophage colony-stimulating factor,
Lenzilumab,
Forward-looking statement,
Cytokine,
Macrophage colony-stimulating factor (Nasdaq: HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab, today announced that the Companys management will present and host meetings with investors and potential partners at the J.P. Morgan Healthcare Conference, held virtually from January 11 to 14, 2021.
Key Points:
- (Nasdaq: HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab, today announced that the Companys management will present and host meetings with investors and potential partners at the J.P. Morgan Healthcare Conference, held virtually from January 11 to 14, 2021.
- We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection.
- Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements.
- You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release.